For example, low-dose IL-2 may aid in restoring Treg numbers and function after hematopoietic stem cell transplantation without concurrent expansion of effector T cell populations, with an improvement in GVHD in around half of patients [72], [73]. This evidence concerns the gene IL2 and graft versus host disease.